BUZZ - Johnson & Johnson stock may see its biggest drop in 18 months due to sluggish sales in medical devices

Latest Updates

October 13 - ** Johnson & Johnson (JNJ.N) shares fell by 6.9% to $245.48 , hitting a new low in over three months

** If the decline continues, it will mark the biggest single-day percentage drop since April 2025

** According to data compiled by London Stock Exchange Group (LSEG), Johnson & Johnson's third-quarter MedTech sales rose 2.5% to $8.6 billion, missing analysts' expectation of $8.71 billion

** Overall, based on LSEG data, adjusted earnings per share for the third-quarter came in at $2.59, above the expected $2.54; revenue was $25.4 billion, surpassing the forecasted $25.28 billion

** “While the overall results were broadly in-line, we believe investors will be disappointed with some of the details,” Guggenheim analyst Vamil Divan said, noting that the MedTech business performance was “somewhat underwhelming”

** The company raised its 2026 outlook (link), now expecting to report sales of about $101.2 billion and median adjusted earnings per share of $11.10, up from its previous forecast of about $101.1 billion and $11.04 per share

** According to data compiled by London Stock Exchange Group (LSEG), analysts on average expect 2026 sales of about $101.3 billion and adjusted earnings per share of $11.08

** As of last session’s close, Johnson & Johnson (JNJ) has gained 27.4% this year, outperforming the S&P 500 index .SPX increase of 11.7%

(To assist non-native English speakers, Reuters has automated the translation of its report into several other languages. Automated translations may contain errors or lack the necessary context, and Reuters does not guarantee the accuracy of translated text. The translated version is provided solely for reader convenience, and Reuters assumes no responsibility for any damages or losses arising from the use of automated translation.)